The IPPF is excited to share that in June of 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as the first biologic treatment for adults with bullous pemphigoid (BP). This is a significant milestone for our community and offers a new treatment option for BP patients.
What is Dupixent (dupilumab)?
Dupixent (dupilumab) is an injectable prescription biologic medication that works by targeting specific parts of the immune system involved in inflammation.
- Dupixent is NOT a steroid or an immunosuppressant
- Dupixent targets a key source of underlying inflammation that may contribute to BP
- Dupixent may help achieve sustained remission and reduce itch
Dupixent has been previously approved for other inflammatory diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The approval for bullous pemphigoid represents the first time a biologic has been approved specifically for this rare autoimmune blistering skin disease.
Scientifically Speaking
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often comorbid diseases.
Who Might Benefit?
Dupixent is now approved for adults with bullous pemphigoid. As always, treatment decisions should be made in partnership with your dermatologist or care team. Not all patients will respond the same way, and your provider can help assess if Dupixent is appropriate for your specific case.
What Does Treatment Involve?
Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. Many patients are trained to self-inject, or have a caregiver assist with injections.
DUPIXENT MyWay
DUPIXENT MyWay is a patient support program that can help enable access to Dupixent and offers financial assistance to eligible patients, one-on-one nursing support, and more. Learn more.
Benefits of this program may include:
- benefits investigation
- prior authorization
- appeals
- Quick Start Program
- Copay assistance for eligible commercially insured patients
- Patient Assistance Program for those who are uninsured or on Medicare Part D
- one-on-one nurse educators
- supplemental injection training
More details
We are awaiting further details about how the support program will be tailored to bullous pemphigoid patients and will update this page as more information becomes available.
For information on how to enroll:
Learn More
We will continue to offer educational webinars, patient stories, and clinical updates on Dupixent as information becomes available.